Aileron Unveils Initial Data For Its Chemo Protective Agent

  • Aileron Therapeutics Inc ALRN has announced initial findings from its ongoing study of ALRN-6924 in healthy volunteers. 
  • Data were presented at the International Society for Experimental Hematology (ISEH) 50th Annual Scientific Meeting. 
  • The initial findings demonstrated that a 0.3 mg/kg dose of ALRN-6924 was well tolerated.
  • It resulted in p53-mediated induction of the cell cycle inhibitor p21 in healthy, normal bone marrow cells without concurrent induction of apoptosis.
  • Related Content: Aileron Launches Early-Stage Study For Chemoprotective Candidate In Lung Cancer Settings.
  • Aileron will present final data from the Phase 1b small-cell lung cancer trial and additional data from the healthy volunteer study at the European Society for Medical Oncology (ESMO) Congress.
  • Price Action: ALRN shares are down 3.52% at $1.09 during the market session on the last check Friday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsPenny StocksHealth CareGeneralBriefschemotherapyPhase 1 Trial
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!